ATP-noncompetitive CDK inhibitors for cancer therapy: An overview

Expert Opinion on Investigational Drugs

Volumn 22, Issue 7, 2013, Pages 895-906

  Abate, Agnese Anna ^a   Pentimalli, Francesca ^b   Esposito, Luca ^b   Giordano, Antonio ^a,c  

^a Temple University   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

ATP noncompetitive; Cancer; CDK inhibitors; Cell cycle

Indexed keywords

3 ATA; ANTINEOPLASTIC AGENT; BENZALKONIUM CHLORIDE; CYC 103; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASES INHIBITOR; FLAVOPIRIDOL; NBI 1; ROSCOVITINE; SPA 310; SU 9516; UNCLASSIFIED DRUG; VORINOSTAT;

ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; COLON CANCER; COLORECTAL CANCER; COMPUTER AIDED DESIGN; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IC 50; LEUKEMIA; LIVER CELL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MESOTHELIOMA; OSTEOSARCOMA; OVARY CARCINOMA; REVIEW;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL CYCLE; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASES; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN KINASE INHIBITORS; SMALL MOLECULE LIBRARIES;

EID: 84879102756     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.798641     Document Type: Review

References (105)

1. Rubin GM, Yandell MD, Wortman JR, et al. Comparative Genomics of the Eukaryotes Science. 2000;287:2204
2. Manning G, Whyte DB, Martinez R, et al. The Protein Kinase Complement of the Human Genome. Science 2002;298:1912-34
3. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009;28:2925-39
4. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609
5. Nigg EA. Targets of cyclin-dependent protein kinases. Curr Opin Cell Biol 1993;5:187
6. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Ann Rev Pharmacol Toxicol 1999;39:295-312
7. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992;61:441-70
8. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30
9. Genovese C, Trani D, Caputi M, et al. Cell cycle control and beyond: emerging roles for the retinoblastoma gene family. Oncogene 2006;25:5201-9
10. Schaffer BE, Park KS, Yiu G, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 2010;70:3877-83
11. Baldi A, De Luca A, Claudio PP, et al. The RB2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. J Cell Biochem 1995;59:402-8
12. Haigis K, Sage J, Glickman J, et al. The related Retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. J Biol Chem 2006;281:638-47
13. Malumbres M, Harlow E, Hunt T, et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009;11:1275-6
14. Pines J, Hunter T. Cyclin-dependent kinases: a new cell cycle motif? Trends Cell Biol 1991;1:117-21
15. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31
16. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6
17. Pines J. Cyclins, cdks and cancer. Semin Cancer Biol 1995;6:63-72
18. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8
19. Catalogue of somatic mutations in cancer COSMIC, Trust Genome Campus, Hinxton, Cambridge. Available from: http://www.sanger.ac.uk/genetics/CGP/cosmic/ [Last accessed 5 November 2012]
20. Pentimalli F, Giordano A. Promises and drawbacks of targeting cell cycle kinases in cancer. Discov Med 2009;43:177-80
21. Wolfel T, Hauer M, Schneider J, et al. p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4
22. Lapointe J, Lachance Y, Labrie Y, et al. A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res 1996;56:4586-9
23. Shennan MG, Badin A, Walsh S, et al. Lack of germline CDK6 mutations in familial melanoma. Oncogene 2000;19:1849-52
24. Indovina P, Marcelli E, Casina N, et al. Emerging roles of RB family: new defense mechanisms against tumor progression. J Cell Physiol 2013;228:525-35
25. Siddik ZH. Checkpoint controls and targets in cancer therapy. Humana press; Springer New York; 2009
26. Giordano A, McCall C, Whyte P, et al. Human cyclin A and the retinoblastoma protein interact with similar but distinguishable sequences in the adenovirus E1A gene product. Oncogene 1991;6:481-5
27. Giordano A, Lee JH, Scheppler JA, et al. Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A. Science 1991;253:1271-5
28. Giordano A, Whyte P, Harlow E, et al. A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells. Cell 1989;58:981-90
29. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66
30. Galons H, Oumata N, Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Patent 2010;20:377-404
31. Malumbres M, Pevarello P, Barbacid M, et al. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008;29:16-21 y.
32. Thoms HC, Dunlop MG, Stark LA. CDK4 Inhibitors and apoptosis a novel mechanism requiring nucleolar targeting of RelA. Cell Cycle 2007;6:1293-7
33. Ferrer J, Dupuy J, Borel F. Structural basis for the modulation of cdk dependent/independent activity of cyclin D1. Cell Cycle 2006;5:2760-8
34. Davies TG, Pratt DJ, Endicott JA, et al. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol Ther 2002;93:125-33
35. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64
36. Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009;42:1-40
37. Hanks SK, Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 1995;9:576
38. Fischer PM, Gianella-Borradori A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2003;12:955-70
39. Christian BA, Grever MR, Byrd JC, et al. Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr Opin Oncol 2007;19:573-8
40. Takahashi I, Saitoh Y, Yoshida M, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot 1989;42:571-6
41. Akiyama T, Yoshida T, Tsujita T, et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 inp53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997;57:1495-501
42. Akiyama T, Sugiyama K, Shimizu M, et al. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation. Jpn J Cancer Res 1999;90:1364-72
43. Bhonde MR, Hanski ML, Magrini R, et al. The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. Oncogene 2005;24:148-56
44. Malumbres M, Barbacid M. Cell cycle. CDKs, and cancer: a changing paradigm46. Nat Rev Cancer 2009;9:153-66
45. Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007;448:811-15
46. Malumbres M, Barbacid M. Is cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 2006;9:2-4
47. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007;13:4467-73
48. Huang J, Sheard MA, Ji L, et al. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Mol Cancer Ther 2010;9:3289-301
49. De Azevedo WF, Lecrerc S, Meijer L, et al. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997;243:518-26
50. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36
51. Meijer L, Bettayeb K, Galons H. Roscovitine (CYC202, seliciclib). inhibitors of cyclin-dependent kinases as anti-tumor agents. CRC Press, Taylor & Francis group, Boca Raton, FL 33487-2742; 2007
52. Genzyme. Purine derivatives for the treatment of cystic diseases. WO08051502; 2008
53. Benson C, Raynoud F, O'Donnel A, et al. Pharmacokinetics (PK) and oral cyclic dependent kinase inhibitor CYC202 (R-roscovitine) in patients with cancer. Proc Am Assoc Cancer Res 2002;43:1354
54. Stearns ME, Jenkins DP, Tew KD. Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. Proc Natl Acad Sci USA 1985;82:8483-7
55. Summerer D, Chen S, Wu N, et al. A genetically encoded fluorescent amino acid. Proc Natl Acad Sci USA 2006;103:9785-9
56. Damianovich M, Ziv I, Heyman SN, et al. ApoSense: a novel technology for functional molecular imaging of cell death in models of acute renal tubular necrosis. Eur J Nucl Med Mol Imaging 2006;33:281-91
57. Cohen A, Ziv I, Aloya T, et al. Monitoring of chemotherapy-induced cell death in melanoma tumors by N,N'-Didansyl-L-cystine. Technol Cancer Res Treat 2007;6:221-34
58. Kong Y, Jung M, Wang K, et al. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol Cancer Ther 2011;10:1591-9
59. Bhardwaj A, Kaur J, Sharma SK, et al. Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker. Bioorgan Med Chem Lett 2013;23:163-8
60. Joubert J, van Dyk S, Green IR, et al. Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands. Eur J Med Chem 2011;46:5010-20
61. Sheikh KD, Banerjee PP, Jagadeesh S, et al. Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1a and inhibits human prostate xenograft. J Med Chem 2010;53:2376-82
62. Yenugonda VM, Deb TB, Grindrod SC, et al. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem 2011;19:2714-25
63. Albert Einstein College of Medicine of Yeshiva University. Fluorescent assays for screening for protein kinase inhibitors applicable in cancer treatment and diagnosis. WO2004062475
64. Stearns ME, Jenkins DP, Tew KD. Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. Proc Natl Acad Sci USA 1985;82:8483-7
65. Atkinson GE, Cowan A, McInnes C, et al. Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe. Bioorg Med Chem Lett 2002;12:2501-5
66. Rizzolio F, Tuccinardi T, Caligiuri I, et al. CDK Inhibitors: from the bench to clinical trials. Curr Drug Targets 2010;11:279-90
67. Cirillo D, Pentimalli F, Giordano A. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors. Curr Med Chem 2011;18:1-13
68. Adams PD, Sellers WR, Sharma SK, et al. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-Like cyclin-dependent kinase inhibitors. Mol Cell Biol 1996;16:6623-33
69. Canela N, Orzaez M, Fucho R, et al. Identification of an hexapeptide that binds to a surface pocket in cyclin a and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A. J Biol Chem 2006;281:35942-53
70. Vadivelan S, Sinha BN, Irudayam SJ, et al. Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors. J Chem Inf Model 2007;47:1526-35
71. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417-25
72. Russo AA, Jeffrey PD, Pavletich NP. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 1996;3:696-700
73. Lo Conte L, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J Mol Biol 1999;285:2177-98
74. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol 1998;280:1-9
75. Tsai CJ, Lin SL, Wolfson HJ, et al. Protein-protein interfaces: architectures and interactions in protein-protein interfaces and in protein cores. Their similarities and differences. Crit Rev Biochem Mol Biol 1996;1:127-52
76. Stites WE. Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem Rev 1997;97:1233-50
77. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: processing towards the dream. Nat Rev Drug Discov 2004;3:301-17
78. Kubo A, Nakagawa K, Varma RK, et al. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase. Clin Cancer Res 1999;5:4279-86
79. Diccianni MB, Yu J, Meppelink G, et al. 3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner. J Exp Ther Oncol 2004;4:223-37
80. Diccianni MB, Batova A, Yu J, et al. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leuk Res 1997;21:549-58
81. ' Verdaguer E, JordaEG, et al. 3-Amino thioacridone, a selective cyclin-dependent kinase 4 inhibitor, attenuates kainic acid-induced apoptosis in neurons. Neuroscience 2003;120:599-603
82. Moshinsky DJ, Bellamacina CR, Boisvert DC, et al. SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem Biophys Res Commun 2003;310:1026-31
83. Uchiyama H, Sowa Y, Wakada M, et al. Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells. Cancer Sci 2010;101:728-34
84. D'Assoro AB, Busby R, Acu ID, et al. Impaired p53 function leads to centrosome amplification, acquired ERa phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene 2008;27:3901-11
85. Takagi K, Sowa Y, Cevik OM, et al. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells. Int J Oncol 2008;32:1105-10
86. Gao N, Kramer L, Rahmani M, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5- methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol 2006;70:645-55
87. Lane ME, Yu B, Rice A, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001;61:6170-7
88. Lo M, Ngo R, Dai K, et al. Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors. Anal Biochem 2012;421:368-77
89. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;12:1192-7
90. Amgen. Preparation of pyrimidinecarboxamides, pyrimidinylcarbamates and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases. US7504396; 2009
91. Amgen. Preparation of pyrimidinecarboxamides, pyrimidinylcarbamates and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases. WO2005009443; 2005
92. Amgen. Preparation of 2-aminopyrimidines and 2-aminopyridine-4-carbamates for use in the treatment of autoimmune diseases. WO2005009978; 2005
93. Amgen. Preparation of 2-aminopyrimidine-4-carbamates as inhibitors of Lck kinase enzyme. US7442698; 2008
94. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
95. Orzaez M, Guevara T, Sancho M, et al. Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment. Cell Death Discov 2012;3:e415
96. Giordano A, Bellacchio E, Bagella L, et al. Interaction between the Cdk2/cyclin a complex and a small molecule derived from the pRb2/p130 spacer domain. Cell Cycle 2007;6:2591-3
97. Bagella L, Sun A, Tonini T, et al. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 2007;26:1829-39
98. Gondeau C, Gerbal-Chaloin S, Bello P, et al. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J Biol Chem 2005;14:13793-800
99. Morris CM, Gondeau C, Tainer JA, Divita G. Kinetic mechanism of activation of the Cdk2/Cyclin A complex. J Biol Chem 2002;277:23847-53
100. Liu S, Bolger JK, Kirkland LO, et al. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol 2010;12:1169-82
101. Zheleva DI, McInnes C, Gavine AL, et al. Highly potent p21WAF1 derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Peptide Res 2002;60:257-70
102. Ball KL, Lain S, Fahraeus R, et al. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF. Curr Biol 1996;7:71-80
103. Pazos E, Perez M, Gutierrez-de-Teran H, et al. Rational design of a cyclin A fluorescent peptide sensor. Org Biomol Chem 2011;9:7629-32
104. Andrews MJI, McInnes C, Kontopidis G. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org Biomol Chem 2004;2:2735-41
105. Takeda DY, Wohlschlegel JA, Dutta A. A bipartite substrate recognition motif for cyclin-dependent kinases. J Biol Chem 2001;276:1993-7